ACCEPT 3.0: Recalibrating ACute COPD Exacerbation Prediction Tool (ACCEPT) for global use
Authors:
- Laura Huey Mien LimLLLaura Huey Mien Lim
- Jeenat MehareenJMJeenat Mehareen
- Amin AdibiAAAmin Adibi
- Christer JansonChrister Janson
- Pierre-Régis BurgelPierre-Régis Burgel
- Hana MüllerováHMHana Müllerová
- Della VargheseDVDella Varghese
- Jonathan MarshallJMJonathan Marshall
- Surya P. BhattSBSurya P. Bhatt
- Don SinDSDon Sin
- Wenjia ChenWenjia Chen
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Diagnostic and Prognostic Research
- Vol. 10 (1) , 27
Abstract
Background: The ACute COPD Exacerbation Prediction Tool (ACCEPT) is an algorithm for predicting 12-month risk of chronic obstructive pulmonary disease (COPD) exacerbations. To make it suitable for international use, we externally validated and recalibrated ACCEPT 2.0 to incorporate country-specific background exacerbation risk, using multi-country data from NOVELTY (a NOVEL observational longiTudinal studY). Methods: Our study cohort included patients aged $$\:\ge\:$$ 40 years with physician-diagnosed COPD and $$\:\ge\:$$ 30 days of follow-up. We predicted the occurrence of any moderate-to-severe (primary endpoint) and severe (secondary) exacerbations at 12 months, using country-level random effects to account for between-country differences in background exacerbation risks unexplained by predictor effects. We assessed model performance via discrimination, calibration, and net benefit. Results: The analysis sample comprised 5,181 patients (59.4% male, mean age at baseline 66.5 years) from 18 countries, with a mean follow-up of 357 days. 12-month risks ranged between 0.11 and 0.46 (mean = 0.26) for moderate-to-severe and 0.03–0.21 (mean = 0.08) for severe exacerbations. Without country-level adjustment, ACCEPT 2.0’s area under the receiver operating characteristic curve (AUROC) was 0.73 (95% CI 0.72–0.75) and 0.76 (95% CI 0.73–0.78) for moderate-to-severe and severe exacerbations, respectively. However, ACCEPT 2.0 consistently overpredicted risks (observed-to-expected [O/E] risk ratio = 0.57 [95% CI 0.54–0.60] and 0.51 [95% CI 0.46–0.56]). After country-level recalibration, ACCEPT 3.0 showed similar AUROCs (0.75 and 0.76) but substantially improved calibration (O/E ratios: 0.99 [95% CI 0.94–1.05] and 0.99 [95% CI 0.90–1.09]). The net benefit of ACCEPT 3.0 exceeded ACCEPT 2.0 across treatment thresholds of 5%-20%. Conclusion: Recalibrating ACCEPT 2.0 with country-level effects significantly improved calibration of COPD exacerbation risks. The resulting ACCEPT 3.0 is expected to provide higher clinical utility across a range of treatment thresholds.
Keywords
Funding Information
- Mitacs
- AstraZeneca
This publication has 32 references indexed in Scilit:
- Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2026
- Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung diseaseJournal of Clinical Epidemiology, 2024
- A method for comparing multiple imputation techniques: A case study on the U.S. national COVID cohort collaborativeJournal of Biomedical Informatics, 2023
- Generalizability of Risk Stratification Algorithms for Exacerbations in COPDChest, 2022
- ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT)eClinicalMedicine, 2022
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Respiratory Medicine, 2017
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Development and validation of a prediction model with missing predictor data: a practical approachJournal of Clinical Epidemiology, 2010
- Geographic Variation in Chronic Obstructive Pulmonary Disease Exacerbation RatesJournal of General Internal Medicine, 2007
- Minimal Clinically Important Difference—Exacerbations of COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005